Dihydroartemisinin Loaded Nanostructured Lipid Carriers: Evaluation of Pharmacokinetics and Tissue Distribution After Intravenous Administration to Rats

    September 2010 in “ PubMed ”
    Xiaoyun Zhang, Hua Qiao, Jianping Liu, Haijun Dong, Chenlin Shen, Jingman Ni, Yanbin Shi, Ying Xu
    TLDR DHA-NLC may improve drug delivery and reduce side effects for cancer treatment.
    The study evaluated the pharmacokinetics and tissue distribution of dihydroartemisinin (DHA) when delivered via nanostructured lipid carriers (DHA-NLC) compared to a DHA solution in rats. A liquid chromatography-mass spectrometry (LC-MS/MS) method was used for analysis. Results showed that DHA-NLC had a longer mean residence time (MRT) and higher area under the curve (AUC) values in the liver, spleen, lung, brain, and muscle, but lower in the heart and kidney compared to the DHA solution. The DHA-NLC system demonstrated potential as a sustained-release and drug-targeting system, which could reduce dosage and systemic toxicity for antitumor treatments.
    Discuss this study in the Community →